Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB204 Thorough QT Study in Acne Vulgaris
NCT02581072Phase 1Completed
- Sponsor
- Novan
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Polymer-based Nanoparticles, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of berdazimer in acne vulgaris (4 arms), sponsored by Novan. Primary endpoint: Time-matched baseline adjusted QTcF interval at 15 days. Started Oct 2015; status: completed.
02
Drugs
berdazimer
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02581072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581072.